
Hancock Jaffe Laboratories, Inc. EBITDA 2011-2026 | HJLI
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Hancock Jaffe Laboratories, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 88.4 K | -6.69 M | -7.4 M | -5.96 M | -4.51 M | -1.16 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 88.4 K | -7.4 M | -4.27 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 11.68 | -3.87 % | $ 1.75 B | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.21 | 0.48 % | $ 891 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 35.45 | 1.69 % | $ 5.28 K | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 9.38 | -1.37 % | $ 266 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.34 | - | $ 120 M | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.28 | -2.64 % | $ 167 M | ||
|
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.36 | 0.37 % | $ 21.9 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 84.19 | -1.34 % | $ 2.92 B | ||
|
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | ||
|
LENSAR
LNSR
|
-7.7 M | $ 5.9 | -2.8 % | $ 68 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 86.9 | -0.31 % | $ 112 B | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 62.72 | -0.82 % | $ 3.42 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.7 | -1.45 % | $ 29.3 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
-61 M | $ 2.36 | -3.48 % | $ 138 M | ||
|
Delcath Systems
DCTH
|
898 K | $ 8.96 | -1.54 % | $ 321 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 11.86 | -0.08 % | $ 470 M | ||
|
Outset Medical
OM
|
-62.4 M | $ 3.47 | -3.97 % | $ 52.8 K | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Penumbra
PEN
|
207 M | $ 334.37 | -0.35 % | $ 13 B | ||
|
AxoGen
AXGN
|
-1.19 M | $ 31.83 | 0.25 % | $ 1.47 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 36.36 | -0.74 % | $ 1.13 B | ||
|
Insulet Corporation
PODD
|
564 M | $ 223.84 | -1.43 % | $ 15.7 B | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Profound Medical Corp.
PROF
|
-30.3 M | $ 5.21 | -3.52 % | $ 180 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
10.7 M | $ 24.12 | -1.51 % | $ 204 M | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Quanterix Corporation
QTRX
|
-110 M | $ 3.74 | -5.18 % | $ 159 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.66 | -2.02 % | $ 35.9 M | ||
|
Aethlon Medical
AEMD
|
-9 M | $ 2.24 | -2.61 % | $ 3.5 M | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.55 | - | $ 7.07 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 10.74 | 3.52 % | $ 1.45 B | ||
|
Tactile Systems Technology
TCMD
|
35.9 M | $ 26.2 | -1.17 % | $ 599 M | ||
|
IRadimed Corporation
IRMD
|
27.3 M | $ 99.67 | 0.47 % | $ 1.27 B |